Literature DB >> 9484507

Synthesis and anticonvulsant activity of a new class of 2-[(arylalky)amino]alkanamide derivatives.

P Pevarello1, A Bonsignori, P Dostert, F Heidempergher, V Pinciroli, M Colombo, R A McArthur, P Salvati, C Post, R G Fariello, M Varasi.   

Abstract

Although most epilepsies are adequately treated by conventional antiepileptic therapy, there remains an unfulfilled need for safer and more effective anticonvulsant agents. Starting from milacemide, a weak anticonvulsant, and trying to elucidate its mechanism of action, we discovered a structurally novel class of potent and preclinically safe anticonvulsants. Here we report the structure-activity relationship (SAR) study within this series of compounds. Different parts of the structural lead 2-[[4-(3-chlorobenzoxy)benzyl]amino]acetamide (6) were thus varied (Figure 1), and many potent anticonvulsants were found. As an outcome of this study, 57 ((S)-2-[[4-(3-fluorobenzoxy)benzyl]amino]propanamide methanesulfonate, PNU-151774E) emerged as a promising candidate for further development for its potent anticonvulsant activity and outstanding therapeutic indexes (TIs) in different animal tests.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9484507     DOI: 10.1021/jm970599m

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  16 in total

Review 1.  Future prospects for the drug treatment of epilepsy.

Authors:  A Nicolson; J P Leach
Journal:  CNS Drugs       Date:  2001       Impact factor: 5.749

2.  Pressor response to oral tyramine and monoamine oxidase inhibition during treatment with ralfinamide (NW-1029).

Authors:  Andrea F D Di Stefano; Milko Massimiliano Radicioni; Antonio Rusca
Journal:  Neurotox Res       Date:  2012-08-08       Impact factor: 3.911

Review 3.  Safinamide.

Authors:  Ruggero G Fariello
Journal:  Neurotherapeutics       Date:  2007-01       Impact factor: 7.620

4.  Chimeric derivatives of functionalized amino acids and α-aminoamides: compounds with anticonvulsant activity in seizure models and inhibitory actions on central, peripheral, and cardiac isoforms of voltage-gated sodium channels.

Authors:  Robert Torregrosa; Xiao-Fang Yang; Erik T Dustrude; Theodore R Cummins; Rajesh Khanna; Harold Kohn
Journal:  Bioorg Med Chem       Date:  2015-04-11       Impact factor: 3.641

5.  Merging Structural Motifs of Functionalized Amino Acids and α-Aminoamides Results in Novel Anticonvulsant Compounds with Significant Effects on Slow and Fast Inactivation of Voltage-gated Sodium Channels and in the Treatment of Neuropathic Pain.

Authors:  Yuying Wang; Sarah M Wilson; Joel M Brittain; Matthew S Ripsch; Christophe Salomé; Ki Duk Park; Fletcher A White; Rajesh Khanna; Harold Kohn
Journal:  ACS Chem Neurosci       Date:  2011-06-15       Impact factor: 4.418

6.  Merging the structural motifs of functionalized amino acids and alpha-aminoamides: compounds with significant anticonvulsant activities.

Authors:  Christophe Salomé; Elise Salomé-Grosjean; James P Stables; Harold Kohn
Journal:  J Med Chem       Date:  2010-05-13       Impact factor: 7.446

7.  Discovery of Vixotrigine: A Novel Use-Dependent Sodium Channel Blocker for the Treatment of Trigeminal Neuralgia.

Authors:  David R Witty; Giuseppe Alvaro; Dominique Derjean; Gerard M P Giblin; Kevin Gunn; Charles Large; David T Macpherson; Valerie Morisset; Davina Owen; Joanne Palmer; Francois Rugiero; Simon Tate; Christopher A Hinckley; Himanshu Naik
Journal:  ACS Med Chem Lett       Date:  2020-07-16       Impact factor: 4.345

8.  Pressor response to oral tyramine during co-administration with safinamide in healthy volunteers.

Authors:  Andrea Francesco Daniele Di Stefano; Antonio Rusca
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2011-08-19       Impact factor: 3.000

9.  Chimeric agents derived from the functionalized amino acid, lacosamide, and the α-aminoamide, safinamide: evaluation of their inhibitory actions on voltage-gated sodium channels, and antiseizure and antinociception activities and comparison with lacosamide and safinamide.

Authors:  Ki Duk Park; Xiao-Fang Yang; Erik T Dustrude; Yuying Wang; Matthew S Ripsch; Fletcher A White; Rajesh Khanna; Harold Kohn
Journal:  ACS Chem Neurosci       Date:  2014-12-09       Impact factor: 4.418

10.  Randomized trial of safinamide add-on to levodopa in Parkinson's disease with motor fluctuations.

Authors:  Rupam Borgohain; J Szasz; P Stanzione; C Meshram; M Bhatt; D Chirilineau; F Stocchi; V Lucini; R Giuliani; E Forrest; P Rice; R Anand
Journal:  Mov Disord       Date:  2013-12-09       Impact factor: 10.338

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.